Intra-Cellular Therapies Total Long Term Liabilities 2013-2024 | ITCI

Intra-Cellular Therapies total long term liabilities for the quarter ending September 30, 2024 were $0.014B, a 2.77% decline year-over-year.

  • Intra-Cellular Therapies total long term liabilities for 2023 were $0.013B, a 13.88% decline from 2022.
  • Intra-Cellular Therapies total long term liabilities for 2022 were $0.015B, a 17.14% decline from 2021.
  • Intra-Cellular Therapies total long term liabilities for 2021 were $0.019B, a 20.87% decline from 2020.

Intra-Cellular Therapies Total Long Term Liabilities 2013-2024 | ITCI

  • Intra-Cellular Therapies total long term liabilities for 2023 were $0.013B, a 13.88% decline from 2022.
  • Intra-Cellular Therapies total long term liabilities for 2022 were $0.015B, a 17.14% decline from 2021.
  • Intra-Cellular Therapies total long term liabilities for 2021 were $0.019B, a 20.87% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$129.4B
Gilead Sciences (GILD)$121.9B
Bristol Myers Squibb (BMY)$111B
CSL (CSLLY)$91.9B
Regeneron Pharmaceuticals (REGN)$90.6B
GSK (GSK)$76B
Argenex SE (ARGX)$35.4B
Alnylam Pharmaceuticals (ALNY)$35.1B
BioNTech SE (BNTX)$25.7B
Biogen (BIIB)$25.3B
Illumina (ILMN)$24.6B
BeiGene (BGNE)$20.1B
Moderna (MRNA)$19.3B
Incyte (INCY)$15.9B
Genmab (GMAB)$15.3B
Insmed (INSM)$12.8B
Vaxcyte (PCVX)$12.8B
BioMarin Pharmaceutical (BMRN)$12.8B
Bio-Techne Corp (TECH)$12.1B
Sarepta Therapeutics (SRPT)$11.5B
Exelixis (EXEL)$10.2B
QIAGEN (QGEN)$10.1B
Revolution Medicines (RVMD)$9.9B
Exact Sciences (EXAS)$9.9B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$8.1B
Ascendis Pharma (ASND)$7.7B
Viking Therapeutics (VKTX)$7.7B